VistaGen Therapeutics, Inc. Shareholders Equity (Total)

Shareholders Equity (Total) of VTGN for past 10 years: annual, quarterly and twelve month trailing (TTM) including Shareholders Equity (Total) growth rates and interactive chart. Shareholder equity, also referred to as shareholders' equity and stockholders' equity, it a corporation's owners' residual claim after debts have been paid. Equity is equal to a firm's total assets minus its total liabilities. It is found on a company's balance sheet and it's the total equity available to common shareholders (after accounting for preferred equity). Also called book value or net book value.

Highlights and Quick Summary

  • Shareholders Equity (Total) for the quarter ending December 30, 2020 was $93.8 Million (a 2121.63% increase compared to previous quarter)
  • Year-over-year quarterly Shareholders Equity (Total) decreased by -1737.36%
  • Annual Shareholders Equity (Total) for 2020 was $-5.73 Million (a -180.98% decrease from previous year)
  • Annual Shareholders Equity (Total) for 2019 was $7.08 Million (a 2.29% increase from previous year)
  • Annual Shareholders Equity (Total) for 2018 was $6.92 Million (a 1023.19% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Shareholders Equity (Total) of VistaGen Therapeutics, Inc.

Most recent Shareholders Equity (Total)of VTGN including historical data for past 10 years.

Interactive Chart of Shareholders Equity (Total) of VistaGen Therapeutics, Inc.

VistaGen Therapeutics, Inc. Shareholders Equity (Total) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 $93.81 $4.22 $-5.61 $-5.73 $-5.73
2019 $-6.09 $-3.63 $1.63 $7.08 $7.08
2018 $1.69 $3.99 $3.22 $6.92 $6.92
2017 $10.26 $-1.67 $-0.61 $0.62 $0.62
2016 $2.59 $4.09 $6.16 $-2.98 $-2.98
2015 $-1.6 $-1.32 $-2.87 $-20.54 $-20.54
2014 $-17.78 $-17.37 $-15.39 $-12.8 $-12.8
2013 $-12.8 $-12.75 $-11.95 $-12.56 $-12.56
2012 $-10.52 $-6.46 $-6.28 $-5.71 $-5.71
2011 $-4.76 $-8.72 $-7.07 $-32.88 $-32.88
2010 $-0.0 $0.0 $-0.0

Business Profile of VistaGen Therapeutics, Inc.

Sector: Healthcare
Industry: Biotechnology
VistaGen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing various medicines with the potential to care for anxiety, depression, and other disorders of the central nervous system (CNS). The company's CNS pipeline includes PH94B, a rapid-onset neuroactive nasal spray, which is in preparation for Phase III development for the acute treatment of anxiety in adults with social anxiety disorder. Its PH94B product also has potential to treat a range of anxiety disorders, including adjustment disorder with anxiety, postpartum anxiety, post-traumatic stress disorder, preprocedural anxiety, panic, and others. The company's CNS pipeline also comprises PH10, a rapid-onset neuroactive nasal spray, which is in preparation for Phase 2B clinical development as a stand-alone treatment for major depressive disorder (MDD); and AV-101, an oral N-methyl-D-aspartate receptor antagonist, which is in development in combination with probenecid as a potential treatment of levodopa-induced dyskinesia, MDD, neuropathic pain, and suicidal ideation. It has contract research and development agreement with Cato Research Ltd.; license and option agreements with Pherin Pharmaceuticals, Inc.; license and collaboration agreement with EverInsight Therapeutics Inc.; and license and sublicense agreement with BlueRock Therapeutics, LP. The company was founded in 1998 and is headquartered in South San Francisco, California.